Stockscreener 앱 받기
21.72
0.37%
-0.08
시간 외 거래:
22.00
0.28
+1.29%
전일 마감가:
$21.80
열려 있는:
$21.88
하루 거래량:
1.12M
Relative Volume:
0.60
시가총액:
$3.72B
수익:
$1.10B
순이익/손실:
$375.65M
주가수익비율:
9.8894
EPS:
2.1963
순현금흐름:
$113.59M
1주 성능:
-2.82%
1개월 성능:
-0.09%
6개월 성능:
-9.99%
1년 성능:
+23.97%
1일 변동 폭
$21.57
$22.10
1주일 범위
$21.36
$23.07
52주 변동 폭
$16.97
$28.35
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
명칭
Acadia Pharmaceuticals Inc
전화
858-558-2871
주소
12830 EL CAMINO REAL, SAN DIEGO
Compare ACAD vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
21.72 | 3.73B | 1.10B | 375.65M | 113.59M | 2.1963 |
VRTX
Vertex Pharmaceuticals Inc
|
448.29 | 110.45B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
723.41 | 74.73B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
812.81 | 50.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
292.03 | 38.03B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
315.07 | 32.24B | 5.76B | 514.49M | 1.10B | 4.4813 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-25 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2026-02-24 | 개시 | Wolfe Research | Outperform |
| 2026-02-23 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2025-10-21 | 개시 | Citigroup | Buy |
| 2025-05-21 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-02-11 | 개시 | Deutsche Bank | Hold |
| 2025-01-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-08-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-27 | 개시 | BMO Capital Markets | Outperform |
| 2024-03-12 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2024-03-12 | 재확인 | Needham | Buy |
| 2024-01-30 | 개시 | Robert W. Baird | Outperform |
| 2024-01-24 | 업그레이드 | Needham | Hold → Buy |
| 2023-12-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-14 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-12-13 | 개시 | Citigroup | Buy |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-11-06 | 업그레이드 | Mizuho | Neutral → Buy |
| 2023-10-17 | 개시 | UBS | Buy |
| 2023-10-10 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-01-03 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-11-04 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-11-01 | 개시 | Loop Capital | Hold |
| 2022-08-08 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-08-05 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-06-21 | 다운그레이드 | Jefferies | Buy → Underperform |
| 2022-06-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-03-16 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2022-02-09 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2022-01-05 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-12-21 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-11-01 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-10-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | 재개 | Needham | Hold |
| 2021-06-10 | 개시 | Berenberg | Hold |
| 2021-04-07 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2021-04-06 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2021-04-06 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-04-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-04-06 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2021-04-05 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2021-03-10 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-03-09 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-03-09 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-03-09 | 재확인 | H.C. Wainwright | Buy |
| 2021-03-09 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2021-03-09 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-12-16 | 개시 | Mizuho | Buy |
| 2020-11-16 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-08-20 | 개시 | Morgan Stanley | Overweight |
| 2020-07-07 | 업그레이드 | Stifel | Hold → Buy |
| 2020-04-16 | 개시 | Jefferies | Buy |
| 2020-03-31 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-03-06 | 개시 | Citigroup | Buy |
| 2019-12-16 | 개시 | Guggenheim | Buy |
| 2019-10-24 | 개시 | Oppenheimer | Perform |
| 2019-10-01 | 개시 | RBC Capital Mkts | Outperform |
| 2019-09-13 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-10 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2019-07-23 | 재확인 | Needham | Buy |
| 2018-12-10 | 개시 | Canaccord Genuity | Hold |
| 2018-09-21 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2018-08-09 | 재확인 | Stifel | Hold |
| 2018-08-07 | 개시 | Stifel | Hold |
| 2018-08-06 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2017-10-06 | 재개 | Goldman | Neutral |
모두보기
Acadia Pharmaceuticals Inc 주식(ACAD)의 최신 뉴스
ACADIA Pharmaceuticals Targets $1B Brand Opportunity as Key Neuropsychiatry Data Looms - sharewise.com
Acadia Pharmaceuticals (ACAD) lags Q1 earnings and revenue estimates - MSN
ACADIA Pharmaceuticals Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now - 富途牛牛
Earnings Miss: ACADIA Pharmaceuticals Inc. Missed EPS By 58% And Analysts Are Revising Their Forecasts - Yahoo Finance
(ACAD) Volatility Zones as Tactical Triggers - Stock Traders Daily
A Look At ACADIA Pharmaceuticals (ACAD) Valuation After Mixed Q1 2026 Results And EU Trofinetide Setback - simplywall.st
Acadia reaffirms 2026 total revenue guidance of $1.22B-$1.28B as remlifanserin Phase II ADP readout nears - MSN
Acadia Pharmaceuticals (ACAD) Margin Expansion To 34.3% Tests Bearish Growth Concerns - Sahm
What ACADIA Pharmaceuticals (ACAD)'s Earnings Miss, EU Setback and R&D Transition Means For Shareholders - Yahoo Finance
ACAD Maintained by Citigroup -- Price Target Lowered to $32 - GuruFocus
ACADIA Pharmaceuticals stock (US0042251084): Focus on CNS drug pipeline and commercial execution - AD HOC NEWS
ACAD Stock Price, Quote & Chart | ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) - ChartMill
ACADIA Pharmaceuticals Signals Confident Path After Q1 Call - TipRanks
ACADIA Pharmaceuticals Q1 2026 Earnings Call Highlights – DAYBUE and NUPLAZID UpdateNews and Statistics - IndexBox
ACADIA: Buy Rating Reiterated on Durable Commercial Strength and Pipeline Catalysts; $37 Price Target Maintained - TipRanks
H.C. Wainwright Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $37 - Moomoo
Earnings call transcript: ACADIA Pharmaceuticals misses Q1 2026 EPS forecast By Investing.com - Investing.com South Africa
ACAD Q1 Earnings & Revenues Miss Estimates Despite Y/Y Sales Growth - The Globe and Mail
Canaccord reiterates Acadia Pharmaceuticals stock rating on Q1 results By Investing.com - Investing.com South Africa
ACADIA Pharmaceuticals Q1 2026 Earnings Call Transcript - MarketBeat
Canaccord reiterates Acadia Pharmaceuticals stock rating on Q1 results - Investing.com UK
Acadia Pharmaceuticals Q1 2026 Financial Results: DAYBUE and NUPLAZID Sales Growth, Reaffirms Full Year Guidance - Minichart
Acadia (ACAD) Q1 2026 Earnings Transcript - AOL.com
Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance - BioSpace
ACADIA Pharmaceuticals Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:ACAD) 2026-05-06 - Seeking Alpha
ACADIA (NASDAQ: ACAD) posts Q1 2026 sales gains but lower profit - Stock Titan
Earnings call transcript: ACADIA Pharmaceuticals misses Q1 2026 EPS forecast - Investing.com Nigeria
ACADIA Pharmaceuticals Q1 Earnings Call Highlights - Yahoo Finance
MSN Money - MSN
Acadia Pharmaceuticals (ACAD) Lags Q1 Earnings and Revenue Estimates - Yahoo Finance
Earnings Scheduled For May 6, 2026 - Benzinga
Acadia (NASDAQ: ACAD) reaffirms 2026 outlook after Q1 results - Stock Titan
Acadia Pharmaceuticals (NASDAQ:ACAD) Q1 2026 Earnings Miss Sends Stock Lower - ChartMill
ACADIA PHARMACEUTICALS ($ACAD) Releases Q1 2026 Earnings - Quiver Quantitative
Acadia: Q1 Earnings Snapshot - WKYC
Acadia posts $268M quarter as Alzheimer’s study nears fall data - Stock Titan
ACADIA Pharmaceuticals earnings up next: Can drug sales sustain momentum? By Investing.com - Investing.com South Africa
ACADIA Pharmaceuticals earnings up next: Can drug sales sustain momentum? - Investing.com Australia
R&D Leadership Transition and Trial Continuity Could Be A Game Changer For ACADIA Pharmaceuticals (ACAD) - Sahm
Acadia Pharmaceuticals CFO Mark Schneyer sells $76,395 in stock By Investing.com - Investing.com Canada
Acadia Pharmaceuticals officer Kihara sells $29,024 stock By Investing.com - Investing.com India
Acadia Pharmaceuticals CFO Mark Schneyer sells $76,395 in stock - Investing.com
Acadia Pharmaceuticals officer Kihara sells $29,024 stock - Investing.com
ACADIA PHARMACEUTICALS (NASDAQ: ACAD) officer sells shares for RSU tax withholding - Stock Titan
Acadia Pharmaceuticals (ACAD) CFO sells shares to cover RSU taxes - Stock Titan
FDA Approval for NUPLAZID issued to ACADIA PHARMS INC - Quantisnow
ACADIA Pharmaceuticals (ACAD) Q1 2026 Preview: EPS Est. $0.08, Reports May 6 - AlphaStreet
Acadia Pharmaceuticals Inc (ACAD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
자본화:
|
볼륨(24시간):